Improved Oral Absorption of Enteric Coprecipitates of a Poorly Soluble Drug
An anticancer agent,N-[[[4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl]amino]carbonyl]-2-nitrobenzamide (HO-221,1), shows poor oral absorption and is only slightly soluble in water (0.055 μg/mL at 37 °C). The coprecipitates with polyvinylpyrrolidone or a vinyl-pyrrolidone and vinylacetate copolymer (c...
Gespeichert in:
| Veröffentlicht in: | Journal of pharmaceutical sciences 1994-04, Vol.83 (4), p.566-570 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 570 |
|---|---|
| container_issue | 4 |
| container_start_page | 566 |
| container_title | Journal of pharmaceutical sciences |
| container_volume | 83 |
| creator | Kondo, Nobuo Iwao, Toro Hirai, Ken-Ichi Fukuda, Motoko Yamanouchi, Kouichi Yokoyama, Kazumasa Miyaji, Mikio Ishihara, Yoshiaki Kon, Kenji Ogawa, Yasuo Mayumi, Tadanori |
| description | An anticancer agent,N-[[[4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl]amino]carbonyl]-2-nitrobenzamide (HO-221,1), shows poor oral absorption and is only slightly soluble in water (0.055 μg/mL at 37 °C). The coprecipitates with polyvinylpyrrolidone or a vinyl-pyrrolidone and vinylacetate copolymer (copolyvidone) showed a marked increase of the dissolution rate and attainment of temporary supersaturation of1. The oral bioavailability of these preparations in dogs at a dose of1of 5 mg/kg was ∼60%, which was 3.5 times greater than that of a micronized preparation. Further, the enteric coprecipitate with hydroxypropyl methylcellulose phthalate 200731, which showed a dissolution profile similar to that of the copolyvidone preparation at pH 6.5 but no dissolution at pH 1.2, revealed the almost complete oral absorption. Because intraduodenal administration of the copolyvidone coprecipitate showed a higher absorption than that of per oral administration, it was suggested that the partial precipitation of crystallites in the nonenteric coprecipitates occurred before reaching the absorption site, the small intestine. |
| doi_str_mv | 10.1002/jps.2600830425 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76628811</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354915494377</els_id><sourcerecordid>76628811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4375-cf6bfd929b79dc2ba1fda6ab72ea89176f564a5fd62f2617983a73add8aea7b13</originalsourceid><addsrcrecordid>eNqFkUtv1DAURi0EKkNhyw4pC8Qug-0kdrKspg8KVVs0RV1aN_Y1csnEqZ0U5t_jUUaDWCBWXnznvo4JecvoklHKPz4McckFpXVBS149IwtWcZoLyuRzskgAz4uqbF6SVzE-UEoFraojclTTUggmFuTL5WYI_glNdhOgy07a6MMwOt9n3mZn_YjB6Wzlh4DaDW6EEeMugezW-9Bts7XvprbD7DRM31-TFxa6iG_27zH5dn52t_qUX91cXK5OrnJdFrLKtRWtNQ1vWtkYzVtg1oCAVnKEumFS2EqUUFkjuOWCyaYuQBZgTA0IsmXFMfkw902bP04YR7VxUWPXQY9-ikoKweua7cDlDOrgYwxo1RDcBsJWMap29lSyp_7YSwXv9p2ndoPmgO91pfz9PoeoobMBeu3iASuT9TQ6Yc2M_XQdbv8zVH2-Xf-1Qj7Xujjir0MthB9KyKRP3V9fqK-n1-s7dn6vdrPqmcdk_MlhUFE77DUal_5sVMa7f137G7FvqnY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76628811</pqid></control><display><type>article</type><title>Improved Oral Absorption of Enteric Coprecipitates of a Poorly Soluble Drug</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Kondo, Nobuo ; Iwao, Toro ; Hirai, Ken-Ichi ; Fukuda, Motoko ; Yamanouchi, Kouichi ; Yokoyama, Kazumasa ; Miyaji, Mikio ; Ishihara, Yoshiaki ; Kon, Kenji ; Ogawa, Yasuo ; Mayumi, Tadanori</creator><creatorcontrib>Kondo, Nobuo ; Iwao, Toro ; Hirai, Ken-Ichi ; Fukuda, Motoko ; Yamanouchi, Kouichi ; Yokoyama, Kazumasa ; Miyaji, Mikio ; Ishihara, Yoshiaki ; Kon, Kenji ; Ogawa, Yasuo ; Mayumi, Tadanori</creatorcontrib><description>An anticancer agent,N-[[[4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl]amino]carbonyl]-2-nitrobenzamide (HO-221,1), shows poor oral absorption and is only slightly soluble in water (0.055 μg/mL at 37 °C). The coprecipitates with polyvinylpyrrolidone or a vinyl-pyrrolidone and vinylacetate copolymer (copolyvidone) showed a marked increase of the dissolution rate and attainment of temporary supersaturation of1. The oral bioavailability of these preparations in dogs at a dose of1of 5 mg/kg was ∼60%, which was 3.5 times greater than that of a micronized preparation. Further, the enteric coprecipitate with hydroxypropyl methylcellulose phthalate 200731, which showed a dissolution profile similar to that of the copolyvidone preparation at pH 6.5 but no dissolution at pH 1.2, revealed the almost complete oral absorption. Because intraduodenal administration of the copolyvidone coprecipitate showed a higher absorption than that of per oral administration, it was suggested that the partial precipitation of crystallites in the nonenteric coprecipitates occurred before reaching the absorption site, the small intestine.</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1002/jps.2600830425</identifier><identifier>PMID: 8046616</identifier><identifier>CODEN: JPMSAE</identifier><language>eng</language><publisher>Washington: Elsevier Inc</publisher><subject>Administration, Oral ; Animals ; Antineoplastic agents ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - pharmacokinetics ; Benzamides - administration & dosage ; Benzamides - pharmacokinetics ; Biological and medical sciences ; Biological Availability ; Chemistry, Pharmaceutical ; Dogs ; Drug Stability ; General aspects ; Hydrogen-Ion Concentration ; Intestinal Absorption ; Male ; Medical sciences ; Nitrobenzenes - administration & dosage ; Nitrobenzenes - pharmacokinetics ; Pharmacology. Drug treatments ; Powders ; Rats ; Rats, Sprague-Dawley ; Solubility ; X-Ray Diffraction</subject><ispartof>Journal of pharmaceutical sciences, 1994-04, Vol.83 (4), p.566-570</ispartof><rights>1994 Wiley-Liss, Inc., A Wiley Company</rights><rights>Copyright © 1994 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4375-cf6bfd929b79dc2ba1fda6ab72ea89176f564a5fd62f2617983a73add8aea7b13</citedby><cites>FETCH-LOGICAL-c4375-cf6bfd929b79dc2ba1fda6ab72ea89176f564a5fd62f2617983a73add8aea7b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjps.2600830425$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjps.2600830425$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4017628$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8046616$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kondo, Nobuo</creatorcontrib><creatorcontrib>Iwao, Toro</creatorcontrib><creatorcontrib>Hirai, Ken-Ichi</creatorcontrib><creatorcontrib>Fukuda, Motoko</creatorcontrib><creatorcontrib>Yamanouchi, Kouichi</creatorcontrib><creatorcontrib>Yokoyama, Kazumasa</creatorcontrib><creatorcontrib>Miyaji, Mikio</creatorcontrib><creatorcontrib>Ishihara, Yoshiaki</creatorcontrib><creatorcontrib>Kon, Kenji</creatorcontrib><creatorcontrib>Ogawa, Yasuo</creatorcontrib><creatorcontrib>Mayumi, Tadanori</creatorcontrib><title>Improved Oral Absorption of Enteric Coprecipitates of a Poorly Soluble Drug</title><title>Journal of pharmaceutical sciences</title><addtitle>J. Pharm. Sci</addtitle><description>An anticancer agent,N-[[[4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl]amino]carbonyl]-2-nitrobenzamide (HO-221,1), shows poor oral absorption and is only slightly soluble in water (0.055 μg/mL at 37 °C). The coprecipitates with polyvinylpyrrolidone or a vinyl-pyrrolidone and vinylacetate copolymer (copolyvidone) showed a marked increase of the dissolution rate and attainment of temporary supersaturation of1. The oral bioavailability of these preparations in dogs at a dose of1of 5 mg/kg was ∼60%, which was 3.5 times greater than that of a micronized preparation. Further, the enteric coprecipitate with hydroxypropyl methylcellulose phthalate 200731, which showed a dissolution profile similar to that of the copolyvidone preparation at pH 6.5 but no dissolution at pH 1.2, revealed the almost complete oral absorption. Because intraduodenal administration of the copolyvidone coprecipitate showed a higher absorption than that of per oral administration, it was suggested that the partial precipitation of crystallites in the nonenteric coprecipitates occurred before reaching the absorption site, the small intestine.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>Benzamides - administration & dosage</subject><subject>Benzamides - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Biological Availability</subject><subject>Chemistry, Pharmaceutical</subject><subject>Dogs</subject><subject>Drug Stability</subject><subject>General aspects</subject><subject>Hydrogen-Ion Concentration</subject><subject>Intestinal Absorption</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nitrobenzenes - administration & dosage</subject><subject>Nitrobenzenes - pharmacokinetics</subject><subject>Pharmacology. Drug treatments</subject><subject>Powders</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Solubility</subject><subject>X-Ray Diffraction</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtv1DAURi0EKkNhyw4pC8Qug-0kdrKspg8KVVs0RV1aN_Y1csnEqZ0U5t_jUUaDWCBWXnznvo4JecvoklHKPz4McckFpXVBS149IwtWcZoLyuRzskgAz4uqbF6SVzE-UEoFraojclTTUggmFuTL5WYI_glNdhOgy07a6MMwOt9n3mZn_YjB6Wzlh4DaDW6EEeMugezW-9Bts7XvprbD7DRM31-TFxa6iG_27zH5dn52t_qUX91cXK5OrnJdFrLKtRWtNQ1vWtkYzVtg1oCAVnKEumFS2EqUUFkjuOWCyaYuQBZgTA0IsmXFMfkw902bP04YR7VxUWPXQY9-ikoKweua7cDlDOrgYwxo1RDcBsJWMap29lSyp_7YSwXv9p2ndoPmgO91pfz9PoeoobMBeu3iASuT9TQ6Yc2M_XQdbv8zVH2-Xf-1Qj7Xujjir0MthB9KyKRP3V9fqK-n1-s7dn6vdrPqmcdk_MlhUFE77DUal_5sVMa7f137G7FvqnY</recordid><startdate>199404</startdate><enddate>199404</enddate><creator>Kondo, Nobuo</creator><creator>Iwao, Toro</creator><creator>Hirai, Ken-Ichi</creator><creator>Fukuda, Motoko</creator><creator>Yamanouchi, Kouichi</creator><creator>Yokoyama, Kazumasa</creator><creator>Miyaji, Mikio</creator><creator>Ishihara, Yoshiaki</creator><creator>Kon, Kenji</creator><creator>Ogawa, Yasuo</creator><creator>Mayumi, Tadanori</creator><general>Elsevier Inc</general><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley</general><general>American Pharmaceutical Association</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199404</creationdate><title>Improved Oral Absorption of Enteric Coprecipitates of a Poorly Soluble Drug</title><author>Kondo, Nobuo ; Iwao, Toro ; Hirai, Ken-Ichi ; Fukuda, Motoko ; Yamanouchi, Kouichi ; Yokoyama, Kazumasa ; Miyaji, Mikio ; Ishihara, Yoshiaki ; Kon, Kenji ; Ogawa, Yasuo ; Mayumi, Tadanori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4375-cf6bfd929b79dc2ba1fda6ab72ea89176f564a5fd62f2617983a73add8aea7b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>Benzamides - administration & dosage</topic><topic>Benzamides - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Biological Availability</topic><topic>Chemistry, Pharmaceutical</topic><topic>Dogs</topic><topic>Drug Stability</topic><topic>General aspects</topic><topic>Hydrogen-Ion Concentration</topic><topic>Intestinal Absorption</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nitrobenzenes - administration & dosage</topic><topic>Nitrobenzenes - pharmacokinetics</topic><topic>Pharmacology. Drug treatments</topic><topic>Powders</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Solubility</topic><topic>X-Ray Diffraction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kondo, Nobuo</creatorcontrib><creatorcontrib>Iwao, Toro</creatorcontrib><creatorcontrib>Hirai, Ken-Ichi</creatorcontrib><creatorcontrib>Fukuda, Motoko</creatorcontrib><creatorcontrib>Yamanouchi, Kouichi</creatorcontrib><creatorcontrib>Yokoyama, Kazumasa</creatorcontrib><creatorcontrib>Miyaji, Mikio</creatorcontrib><creatorcontrib>Ishihara, Yoshiaki</creatorcontrib><creatorcontrib>Kon, Kenji</creatorcontrib><creatorcontrib>Ogawa, Yasuo</creatorcontrib><creatorcontrib>Mayumi, Tadanori</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kondo, Nobuo</au><au>Iwao, Toro</au><au>Hirai, Ken-Ichi</au><au>Fukuda, Motoko</au><au>Yamanouchi, Kouichi</au><au>Yokoyama, Kazumasa</au><au>Miyaji, Mikio</au><au>Ishihara, Yoshiaki</au><au>Kon, Kenji</au><au>Ogawa, Yasuo</au><au>Mayumi, Tadanori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improved Oral Absorption of Enteric Coprecipitates of a Poorly Soluble Drug</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J. Pharm. Sci</addtitle><date>1994-04</date><risdate>1994</risdate><volume>83</volume><issue>4</issue><spage>566</spage><epage>570</epage><pages>566-570</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><coden>JPMSAE</coden><abstract>An anticancer agent,N-[[[4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl]amino]carbonyl]-2-nitrobenzamide (HO-221,1), shows poor oral absorption and is only slightly soluble in water (0.055 μg/mL at 37 °C). The coprecipitates with polyvinylpyrrolidone or a vinyl-pyrrolidone and vinylacetate copolymer (copolyvidone) showed a marked increase of the dissolution rate and attainment of temporary supersaturation of1. The oral bioavailability of these preparations in dogs at a dose of1of 5 mg/kg was ∼60%, which was 3.5 times greater than that of a micronized preparation. Further, the enteric coprecipitate with hydroxypropyl methylcellulose phthalate 200731, which showed a dissolution profile similar to that of the copolyvidone preparation at pH 6.5 but no dissolution at pH 1.2, revealed the almost complete oral absorption. Because intraduodenal administration of the copolyvidone coprecipitate showed a higher absorption than that of per oral administration, it was suggested that the partial precipitation of crystallites in the nonenteric coprecipitates occurred before reaching the absorption site, the small intestine.</abstract><cop>Washington</cop><pub>Elsevier Inc</pub><pmid>8046616</pmid><doi>10.1002/jps.2600830425</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3549 |
| ispartof | Journal of pharmaceutical sciences, 1994-04, Vol.83 (4), p.566-570 |
| issn | 0022-3549 1520-6017 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_76628811 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Administration, Oral Animals Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Benzamides - administration & dosage Benzamides - pharmacokinetics Biological and medical sciences Biological Availability Chemistry, Pharmaceutical Dogs Drug Stability General aspects Hydrogen-Ion Concentration Intestinal Absorption Male Medical sciences Nitrobenzenes - administration & dosage Nitrobenzenes - pharmacokinetics Pharmacology. Drug treatments Powders Rats Rats, Sprague-Dawley Solubility X-Ray Diffraction |
| title | Improved Oral Absorption of Enteric Coprecipitates of a Poorly Soluble Drug |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T05%3A21%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improved%20Oral%20Absorption%20of%20Enteric%20Coprecipitates%20of%20a%20Poorly%20Soluble%20Drug&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Kondo,%20Nobuo&rft.date=1994-04&rft.volume=83&rft.issue=4&rft.spage=566&rft.epage=570&rft.pages=566-570&rft.issn=0022-3549&rft.eissn=1520-6017&rft.coden=JPMSAE&rft_id=info:doi/10.1002/jps.2600830425&rft_dat=%3Cproquest_cross%3E76628811%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76628811&rft_id=info:pmid/8046616&rft_els_id=S0022354915494377&rfr_iscdi=true |